Emcure Pharmaceuticals jumps on getting nod for acquiring 20.42% stake of Zuventus Healthcare
Emcure Pharmaceuticals is currently trading at Rs. 1337.45, up by 25.10 points or 1.91% from its previous closing of Rs. 1312.35 on the BSE.
The scrip opened at Rs. 1314.95 and has touched a high and low of Rs. 1348.00 and Rs. 1304.65 respectively. So far 1739 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1577.50 on 18-Sep-2024 and a 52 week low of Rs. 890.00 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 1377.35 and Rs. 1291.35 respectively. The current market cap of the company is Rs. 25375.17 crore.
The promoters holding in the company stood at 77.92%, while Institutions and Non-Institutions held 6.51% and 15.57% respectively.
Emcure Pharmaceuticals has received approval for the acquisition of 4,095,180 equity shares, constituting 20.42% of the total issued and paid-up capital of Zuventus Healthcare (Zuventus), a subsidiary of the company, from all its individual shareholders, thereby making Zuventus a wholly-owned subsidiary of the company.
The Board of Directors of the company at its meeting held on June 21, 2025, has approved the same.
Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
